Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.38 |
| ▸ | DRD2 | P14416 | 2/20 | 0.38 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | RBP4 | P02753 | 2/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL477701 | 0.83 | SLC6A4 (0.42) | MEN1KMT2ASLC6A4DRD2SLC6A2 | |
| SCHEMBL5140978 | 0.83 | DRD2 (0.44) | MEN1KMT2ASLC6A4DRD2SLC18A3 | |
| SCHEMBL10297984 | 0.83 | MEN1 (0.40) | MEN1KMT2ASLC6A4DRD2SLC18A3 | |
| SCHEMBL7257808 | 0.80 | PTGDR2 (0.44) | MEN1KMT2ASLC6A4SLC6A2SLC6A3 | |
| SCHEMBL2099816 | 0.79 | RBP4 (0.47) | MEN1KMT2AALDH1A1POLBRBP4 | |
| SCHEMBL477417 | 0.78 | PTGDR2 (0.46) | MEN1KMT2ASLC6A4SLC6A2SLC6A3 | |
| SCHEMBL7670301 | 0.75 | RBP4 (0.41) | MEN1KMT2ADRD2SLC18A3RBP4 | |
| SCHEMBL29805150 | 0.75 | SLC6A2 (0.59) | SLC6A4SLC18A3SLC6A2SLC6A3HTR1A | |
| SCHEMBL12835831 | 0.75 | SLC6A2 (0.59) | SLC6A4SLC18A3SLC6A2SLC6A3HTR1A | |
| SCHEMBL9205861 | 0.74 | MEN1 (0.46) | MEN1KMT2AALDH1A1POLBRBP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11723900-B2 | 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-08-15 | — | — | US | disclosed |
| US-11723900-B2 | 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-08-15 | — | — | US | disclosed |
| US-20220087995-A1 | 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-03-24 | — | — | US | disclosed |
| US-10946007-B2 | 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-03-16 | — | — | US | disclosed |
| US-20200316048-A1 | 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-10-08 | — | — | US | disclosed |
| US-10722504-B2 | 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-07-28 | — | — | US | disclosed |
| US-10441579-B2 | 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-10-15 | — | — | US | disclosed |
| US-20190134019-A1 | 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-05-09 | — | — | US | disclosed |
| US-10206913-B2 | 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-02-19 | — | — | US | disclosed |
| US-10034870-B2 | 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-07-31 | — | — | US | disclosed |
| US-9187423-B2 | Process for preparing 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-11-17 | — | — | US | disclosed |
| US-9162982-B2 | 4-[2-(2-fluorophenoxy methyl)phenyl]piperidine compounds | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-10-20 | — | — | US | disclosed |
| US-20140323735-A1 | PROCESS FOR PREPARING 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-10-30 | — | — | US | disclosed |
| US-8802857-B2 | Process for preparing 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-08-12 | — | — | US | disclosed |
| US-20140057944-A1 | 4-[2-(2-FLUOROPHENOXY METHYL)PHENYL]PIPERIDINE COMPOUNDS | THERAVANCE, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-20130030020-A1 | 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUNDS | THERAVANCE, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-20120277438-A1 | PROCESS FOR PREPARING 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUNDS | THERAVANCE, INC. (US) | 2012-11-01 | — | — | US | disclosed |
| US-8247433-B2 | Process for preparing 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds | THERAVANCE, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-20100125141-A1 | PROCESS FOR PREPARING 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP, LLC | 2010-05-20 | — | — | US | disclosed |
| US-20100125092-A1 | 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP, LLC | 2010-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10946007-B2 | 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds | SLC6A2, SLC6A4, HTR6 | MEN1 917/4885KMT2A 1478/4885SLC6A4 2/4885 |
| US-20200316048-A1 | 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUNDS | SLC6A2, SLC6A4, HTR6 | MEN1 917/4885KMT2A 1478/4885SLC6A4 2/4885 |
| US-11723900-B2 | 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds | SLC6A2, SLC6A4, HTR6 | MEN1 917/4885KMT2A 1478/4885SLC6A4 2/4885 |
| US-10722504-B2 | 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds | SLC6A2, SLC6A4, HTR6 | MEN1 917/4885KMT2A 1478/4885SLC6A4 2/4885 |
| US-20100125092-A1 | 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUNDS | SLC6A2, SLC6A4, HTR6 | MEN1 917/4885KMT2A 1478/4885SLC6A4 2/4885 |
| US-20120277438-A1 | PROCESS FOR PREPARING 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUNDS | SLC6A2, SLC6A4, HTR6 | MEN1 548/4885KMT2A 1467/4885SLC6A4 2/4885 |
| US-10441579-B2 | 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds | SLC6A2, SLC6A4, HTR6 | MEN1 917/4885KMT2A 1478/4885SLC6A4 2/4885 |
| US-20220087995-A1 | 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUNDS | SLC6A2, SLC6A4, HTR6 | MEN1 917/4885KMT2A 1478/4885SLC6A4 2/4885 |
| US-20130030020-A1 | 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUNDS | SLC6A2, SLC6A4, HTR6 | MEN1 917/4885KMT2A 1478/4885SLC6A4 2/4885 |
| US-20100125141-A1 | PROCESS FOR PREPARING 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUNDS | SLC6A2, SLC6A4, HTR6 | MEN1 548/4885KMT2A 1467/4885SLC6A4 2/4885 |
| US-20190134019-A1 | 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUNDS | SLC6A2, SLC6A4, HTR6 | MEN1 917/4885KMT2A 1478/4885SLC6A4 2/4885 |
| US-20140057944-A1 | 4-[2-(2-FLUOROPHENOXY METHYL)PHENYL]PIPERIDINE COMPOUNDS | SLC6A2, SLC6A4, HTR6 | MEN1 744/4885KMT2A 932/4885SLC6A4 2/4885 |
| US-10206913-B2 | 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds | SLC6A2, SLC6A4, HTR6 | MEN1 917/4885KMT2A 1478/4885SLC6A4 2/4885 |
| US-10034870-B2 | 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds | SLC6A2, SLC6A4, HTR6 | MEN1 917/4885KMT2A 1478/4885SLC6A4 2/4885 |
| US-20140323735-A1 | PROCESS FOR PREPARING 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUNDS | SLC6A2, SLC6A4, HTR6 | MEN1 548/4885KMT2A 1467/4885SLC6A4 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.